Triple threat: Low-Dose radiation plus chemo and immunotherapy takes on tough lung cancer

NCT ID NCT05765825

Ongoing Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a new approach for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy (cisplatin or carboplatin plus etoposide) and the immunotherapy drug serplulimab. The goal is to see if this combination can delay cancer progression and improve survival. The study enrolled 61 participants across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: serplulimab (an immunotherapy drug), cisplatin or carboplatin (chemotherapy), etoposide (chemotherapy), and low-dose radiotherapy
What this could lead to: If this works, it could point toward a more effective first-line treatment for extensive-stage small cell lung cancer, potentially improving how long people live without their cancer getting worse.
What could go wrong: This is a small, early-phase (phase 2) study with no comparison group, so results are uncertain. The combination of treatments may cause significant side effects, and it is not yet known if it will be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cancer Hospital of Shantou University Medical College

Shantou, Guangdong, 515041, China
China West Hospital

Chengdu, Sichuan, 610000, China
Chongqing University cancer hospital

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China
GuiZhou Provincial People's Hospital

Guiyang, China
LiaoNing Cancer Hospital & Institute

Shenyang, Liaoning, 110801, China
Shandong Provincial Hospital

Jinan, Shandong, 250021, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.